MAP0004

DRUG5 trials

Sponsors

Allergan

Conditions

HealthyHealthy SubjectsMigraine Disorders

Phase 1

Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure

CompletedNCT01089062

AllerganHealthy

Start: 2010-03-31End: 2010-12-31Updated: 2014-01-09

QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo

CompletedNCT01191723

AllerganHealthy

Start: 2010-08-31End: 2010-09-30Updated: 2014-01-09

Pharmacokinetics & Tolerability Study of MAP0004 in Smoking and Non-Smoking Adult Volunteers

CompletedNCT01199965

AllerganHealthy Subjects

Start: 2010-01-31End: 2010-04-30Updated: 2014-01-09

Pharmacokinetics & Tolerability Study of MAP0004 Co-administered With Ketoconazole

CompletedNCT01468558

AllerganHealthy

Start: 2010-07-31End: 2010-08-31Updated: 2014-01-09

Phase 3

Phase 3 Study of MAP0004 in Adult Migraineurs

CompletedNCT00623636

AllerganMigraine Disorders

Start: 2008-07-31End: 2011-01-31Updated: 2014-01-09

Related Papers

Assessing acute systemic effects of an inhaled drug with serial echocardiography: a placebo-controlled comparison of inhaled and intravenous dihydroergotamine.

2013-07-247 citations

Effects of a supratherapeutic dose of investigational orally inhaled dihydroergotamine (MAP0004) on QT interval: a randomized, double-blind, active- and placebo-controlled crossover study in healthy volunteers.

2012-08-219 citations